Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

There is no fulltext present in this item.

Title:	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Author(s):	Matulonis, U.A.; Shapira-Frommer, R.; Santin, A.D.; Lisyanskaya, A.S.; Pignata, S.; Vergote, I.; Ottevanger, P.B. ; Ruman, J.; Ledermann, J.A.
Publication year:	2019
Source:	Annals of Oncology, vol. 30, iss. 7, (2019), pp. 1080-1087
ISSN:	0923-7534
DOI:	https://doi.org/10.1093/annonc/mdz135
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/207862
Display more details
Subject:	All institutes and research themes of the Radboud University Medical Center Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences
Organization:	Medical Oncology IQ Healthcare
Journal title:	Annals of Oncology
Volume:	vol. 30
Issue:	iss. 7
Page start:	p. 1080
Page end:	p. 1087